Steroid Side Effects in Men: What Actually Happens, How Common Each Side Effect Is, and What Reduces the Risk
Most content about steroid side effects in men falls into one of two categories: scare-tactic lists that treat every possible side effect as inevitable, or dismissive bro-science that treats them all as trivial. Neither is useful. What you need is the actual incidence data: how common is each side effect, what dose and compound factors influence it, and what evidence-based strategies reduce the risk. This guide from Hemi Pharma UK provides exactly that, drawing primarily on the HAARLEM study, the largest prospective observational cohort study of amateur steroid users ever conducted, which tracked 100 men through a self-administered cycle with systematic medical assessment before, during, and after use.
What does the HAARLEM study tell us about how common steroid side effects actually are?
The HAARLEM study (Health risks of Anabolic Androgenic steRoid use by maLE aMateur athletes) is the most reliable source of side effect incidence data available because it is prospective, systematic, and uses medical examination rather than relying entirely on self-report. Conducted at Amsterdam UMC, it enrolled 100 male amateur strength athletes before a self-administered steroid cycle, examined them at baseline, at the end of the cycle, and at three months and one year post-cycle. The mean weekly androgen dose was 898mg, and the median cycle length was 13 weeks.
Every single participant reported at least one negative side effect. Every single participant also reported positive effects. This duality is the reality of steroid use: it is not a question of whether side effects occur, but which ones, at what severity, and whether they resolve. The HAARLEM study published the complete incidence data in Scandinavian Journal of Medicine and Science in Sports, providing the numbers that follow throughout this guide.
How common is acne on a steroid cycle and what causes it?
Acne was the most commonly reported negative side effect in the HAARLEM study. Self-reported acne increased from 10% at baseline to 52% at the end of the cycle. However, physician examination found a smaller increase, from 13% to 29%, because many users classified a few pimples as “acne” that a dermatologist would not. The review by de Ronde and colleagues in Frontiers in Endocrinology noted this discrepancy specifically, suggesting that while steroid-induced acne is genuinely common, its severity is often milder than users perceive.
The mechanism is straightforward. Androgens stimulate sebaceous gland hypertrophy and increase sebum production. Higher sebum output clogs pores, creates an anaerobic environment favourable to Cutibacterium acnes, and triggers the inflammatory cascade that produces comedones, papules, and cystic lesions. The back, shoulders and chest are most affected because sebaceous gland density is highest in these areas.
Compound specificity matters. Testosterone at moderate doses produces mild to moderate acne in susceptible individuals. Trenbolone and other highly androgenic compounds produce more severe outbreaks. DHT derivatives (Masteron, Proviron, Winstrol) are variable: Masteron’s androgenic activity at the sebaceous gland is significant, while Anavar has a low androgenic rating and is among the least likely compounds to cause acne.
Mitigation strategies include: keeping the skin clean without over-washing (which stimulates compensatory sebum production), using a benzoyl peroxide wash (2.5% to 5%) on the back and shoulders, changing bed sheets and gym clothing frequently, and in persistent cases, low-dose isotretinoin (Accutane) under medical supervision, which is the only treatment that directly addresses the overactive sebaceous gland rather than treating symptoms. Isotretinoin should never be started without medical guidance because of its teratogenicity, hepatotoxicity, and psychiatric side effect profile.
How common is hair loss on steroids and can you prevent it?
Self-reported hair loss in the HAARLEM study increased from 2% at baseline to 12% at the end of the cycle. The study did not include an objective measure of alopecia, so it is difficult to distinguish between genuine new hair loss and heightened self-awareness (users check their hairlines more frequently during a cycle). Importantly, hair loss was the only side effect in the HAARLEM dataset that showed a positive association with cycle length: longer cycles meant more hair loss.
Hair loss from steroids is not a universal side effect. It is entirely mediated by genetics. The androgen receptor gene on the X chromosome determines follicle sensitivity to DHT and other androgens. If you carry the susceptibility variant, androgens will miniaturise your follicles. If you do not carry it, you can run substantial doses without losing hair. This is why two users on identical cycles can have completely different hair outcomes.
Compound choice is the most powerful preventive measure. Steroids that convert to DHT via 5-alpha reductase (testosterone) or that are already DHT derivatives (Winstrol, Masteron, Proviron) carry the highest risk. Nandrolone is actually converted to a weaker metabolite (dihydronandrolone) in the scalp by 5-alpha reductase, making it less androgenic at the follicle than testosterone. Anavar has a low androgenic rating and is often recommended for users concerned about hair. Our Anavar hair loss guide covers the evidence in detail.
Finasteride (1mg daily) blocks 5-alpha reductase and prevents the conversion of testosterone to DHT, which reduces follicular androgenic load. However, finasteride only protects against testosterone-derived DHT. It does nothing against compounds that are already DHT derivatives (Winstrol, Masteron) or that exert androgenic effects without 5-alpha reduction (Trenbolone). Topical anti-androgens (RU58841) are used by some bodybuilders but are not FDA-approved and have limited published safety data.
How common is gynaecomastia on steroids and how do you prevent it?
Physician-confirmed gynaecomastia increased from 7% at baseline to 19% at the end of a cycle in the HAARLEM study. Self-reported gynaecomastia was higher at 26%. A separate Dutch outpatient clinic study of 160 steroid users found gynaecomastia in 34%, though this population was self-selected (men attending a clinic are more likely to have problems than men who do not). A 2026 review in Nature Reviews Urology noted that the true prevalence of AAS-associated gynaecomastia may be significantly higher than history-based surveys suggest: a study of gynaecomastia surgery patients found that 39.2% had AAS-associated gynaecomastia on postoperative reassessment, compared with only 4.1% identified from preoperative history alone.
Gynaecomastia from steroids develops through two distinct pathways. The oestrogen-mediated pathway involves aromatisation of testosterone (or Dianabol) to oestradiol, which binds to oestrogen receptors in breast ductal tissue and triggers epithelial proliferation. The prolactin-mediated pathway involves 19-nor compounds (Nandrolone, Trenbolone) elevating prolactin through interaction with the progesterone receptor and suppression of dopaminergic signalling, which stimulates breast tissue growth independently of oestrogen.
Prevention depends on which pathway is relevant. For oestrogen-mediated gynaecomastia, an aromatase inhibitor (Anastrozole) reduces oestradiol production, or a SERM (Tamoxifen) blocks oestrogen receptor binding in breast tissue specifically. Tamoxifen is generally preferred as a preventive measure because it protects the breast tissue without crashing systemic oestrogen levels. For prolactin-mediated gynaecomastia from 19-nor compounds, cabergoline (a dopamine agonist) reduces prolactin levels. Anastrozole does not help with prolactin-mediated gyno because aromatisation is not the cause.
Early warning signs include nipple sensitivity, puffiness around the areola, and palpable tissue (a firm disc behind the nipple). If you catch it early, pharmacological intervention (Tamoxifen 20mg daily) can reverse the proliferative tissue. Once the tissue becomes fibrotic (established, firm, scar-like), surgery (gland excision with or without liposuction) is typically the only resolution.
How common is testicular atrophy and is it permanent?
Testicular atrophy was reported by 58% of HAARLEM study participants during their cycle, making it one of the most common side effects. It is also one of the most predictable: every steroid cycle suppresses LH and FSH, and without gonadotropin stimulation, the Leydig and Sertoli cells of the testes atrophy. The testes physically shrink, typically by 20% to 40% in volume during a standard cycle.
This is almost always fully reversible. Once PCT restores LH and FSH secretion, gonadotropin stimulation resumes, the Leydig and Sertoli cells recover, and testicular volume returns to baseline. The HAARLEM data confirmed recovery in the vast majority of subjects by the one-year follow-up. The exception is prolonged, uninterrupted use over years (blast and cruise without recovery periods), where some degree of permanent testicular atrophy has been observed.
HCG administered during the cycle (250 to 500 IU twice weekly) is the most effective preventive measure. HCG mimics LH and maintains Leydig cell function and intratesticular testosterone throughout the cycle, preventing the worst of the atrophy and making post-cycle recovery faster and more complete. Using HCG on-cycle is increasingly considered standard harm reduction rather than an optional extra.
How common are mood changes and psychological effects on steroids?
Agitation was reported by 27% of HAARLEM participants during the cycle. Mood problems were reported by 16% in the Dutch outpatient clinic cohort. The HAARLEM study also documented a post-cycle “steroid dip” characterised by decreased libido (58%), mood changes, and fatigue as endogenous testosterone recovered.
The psychological effects exist on a spectrum. Most users at moderate doses experience net positive mood effects: increased confidence, motivation, assertiveness, and wellbeing. A subset experience irritability, shortened temper, anxiety, and in rare cases, overt aggression. The relationship is not linear with dose in every individual: some men tolerate 500mg of testosterone weekly with no mood disturbance while others experience significant irritability at 300mg. Individual variation in androgen receptor density in the amygdala and prefrontal cortex, baseline serotonergic function, and pre-existing personality traits all influence the response.
Compound selection has a large effect. Testosterone at moderate doses carries the lowest neuropsychiatric risk. Trenbolone carries the highest, with insomnia, anxiety, and irritability reported so consistently that many experienced users accept these as unavoidable Trenbolone effects rather than side effects to be managed. Nandrolone produces a distinct profile of emotional blunting and reduced motivation in some users, colloquially called “Deca depression,” likely mediated through progesterone receptor activity and dopaminergic suppression.
The post-cycle period is psychologically the most difficult phase. Low endogenous testosterone combined with loss of the on-cycle sense of wellbeing, strength regression, and visual changes (reduced fullness, water loss) can produce genuine depressive symptoms. Effective PCT shortens this window, and understanding that it is temporary and physiologically driven (not a permanent change) is itself protective.
How common are cardiovascular side effects and how do you monitor them?
The HAARLEM study documented significant changes in cardiovascular markers during a single cycle. HDL cholesterol dropped by a median of 31% (with oral steroids producing drops of 50% or more). Haematocrit increased in 13% of subjects to levels requiring clinical attention. Blood pressure increased measurably, though the HAARLEM study did not report a specific hypertension incidence figure. Left ventricular mass increased during the cycle and reversed substantially by follow-up.
These are not side effects you can feel. Unlike acne or mood changes, dyslipidaemia, elevated haematocrit, and early left ventricular hypertrophy are silent until they cause an event. This is the strongest argument for regular bloodwork: without it, the most dangerous side effects are the ones you never know about until they cause damage.
Monitoring strategy: home blood pressure daily (morning and evening, seated, before training, using a validated upper-arm cuff). Full bloodwork at baseline, at mid-cycle (week 6 to 8), at the end of PCT, and at 3 months post-PCT. The critical markers are: full blood count (particularly haematocrit, which should stay below 54%), lipid panel (HDL, LDL, total cholesterol, triglycerides), liver enzymes (if running orals), and kidney function (creatinine, eGFR). Our bloodwork guide covers how to interpret each marker in the context of steroid use.
How common is erectile dysfunction on steroids?
Erectile dysfunction (ED) in the HAARLEM study was reported by 8% at baseline, 12% during the cycle, and 14% at the three-month follow-up (during recovery). The Dutch outpatient clinic found a higher rate of 20%, and among former AAS abusers specifically, ED prevalence was 27.3%. The pattern is clear: ED is most common in the post-cycle period when endogenous testosterone is suppressed and the androgenic environment is at its lowest.
On-cycle ED is usually related to either oestrogen imbalance (too high or, more commonly, too low from excessive AI use) or to 19-nor compounds disrupting the dopamine-prolactin axis. The most common cause of on-cycle ED is crashing oestrogen with Anastrozole or Letrozole. Oestrogen is essential for erectile function: men need adequate oestradiol for libido, erectile quality, and sexual satisfaction. Eliminating oestrogen in pursuit of a “dry” look produces the opposite of the desired effect.
Proviron is frequently used on-cycle specifically for its libido-enhancing effects. It binds SHBG, freeing more testosterone for receptor binding, and has mild anti-oestrogenic properties without crashing oestradiol. Our Proviron libido guide covers the mechanism in detail.
How common is water retention and how do you manage it?
Fluid retention was reported by 56% of HAARLEM participants during the cycle, making it the second most common side effect after testicular atrophy. It is mediated primarily by oestrogen: aromatisation of testosterone to oestradiol activates the aldosterone-ADH system, promoting sodium and water retention in the kidneys. The result is increased extracellular fluid volume, subcutaneous puffiness (particularly in the face, hands and ankles), and increased body weight that does not represent lean tissue.
The degree of water retention is strongly compound-dependent. Testosterone at 300mg to 500mg weekly produces mild to moderate retention. Dianabol and Anadrol produce severe retention. DHT derivatives (Anavar, Winstrol, Masteron) produce no oestrogenic water retention at all.
Management: moderate AI dosing guided by bloodwork (not by mirror assessment), adequate water intake (dehydration paradoxically worsens retention), controlled sodium intake, and potassium-rich foods that support electrolyte balance. Diuretics should never be used without medical supervision: the combination of elevated haematocrit (thicker blood) and diuretic-induced dehydration is a recipe for thromboembolic events.
For verified, independently tested compounds with published Janoshik lab results, Hemi Pharma UK provides full product verification before sale.
Frequently Asked Questions
What percentage of steroid users experience side effects?
In the HAARLEM prospective study, 100% of participants reported at least one negative side effect. The most common were testicular atrophy (58%), fluid retention (56%), acne (52% self-reported, 29% physician-confirmed), gynaecomastia (26% self-reported, 19% physician-confirmed), agitation (27%), and hair loss (12%). However, the study also noted that most side effects were anticipated, mild, and transient, and that all participants simultaneously reported positive effects including increased strength (100%) and increased muscle mass (88%).
Are steroid side effects worse with oral or injectable steroids?
Oral 17-alpha-alkylated steroids add hepatotoxicity and more severe lipid disruption (particularly HDL suppression) that injectables do not cause. Injectables produce more stable blood levels, which generally means fewer mood-related side effects and more predictable oestrogen management. Overall, injectable steroids have a more favourable side effect profile for most use cases, which is why they are used as the cycle base while orals are limited to short-term additions.
Do steroid side effects go away when you stop?
Most side effects resolve after discontinuation and appropriate post-cycle recovery. Acne clears within weeks to months. Lipids normalise within 6 to 10 weeks. Testicular volume recovers. Mood returns to baseline once endogenous testosterone recovers. The side effects most likely to persist are hair loss in genetically susceptible individuals, atherosclerotic plaque accumulated during use, and in a minority of long-term users, incomplete HPTA recovery requiring ongoing testosterone replacement.
Which steroid has the fewest side effects?
Testosterone at TRT-level doses (100mg to 200mg weekly) has the mildest overall side effect profile because it is the endogenous hormone administered at near-physiological levels. Among compounds used at supraphysiological doses, Anavar (Oxandrolone) is generally considered to have the fewest side effects: it does not aromatise, has a low androgenic rating, causes minimal water retention, and has relatively modest impact on lipids compared to other orals, though it is still hepatotoxic and HPTA-suppressive.
Can you prevent all steroid side effects?
No. Some side effects (HPTA suppression and testicular atrophy) are inherent to the mechanism of action and occur in every user. Others (acne, hair loss, gynaecomastia) are influenced by genetics and compound choice but cannot be guaranteed absent. What you can do is reduce the probability and severity of each side effect through compound selection, dose management, ancillary use guided by bloodwork, and cycle length limitation. The goal is informed risk management, not risk elimination.
References
Smit DL, Buijs MM, de Hon O, den Heijer M, de Ronde W. Positive and negative side effects of androgen abuse: the HAARLEM study, a one-year prospective cohort study in 100 men. Scand J Med Sci Sports. 2021;31(2):427-438. Amsterdam UMC Repository
de Ronde W, Smit DL. Anabolic-androgenic steroids: how do they work and what are the risks? Front Endocrinol. 2022;13:1059473. Frontiers in Endocrinology
Nieschlag E, Vorona E. Health consequences of anabolic steroids: a sexual-medicine perspective. Int J Impot Res. 2026. Nature Reviews
Smit DL, de Hon O, Voogel AJ, den Heijer M, de Ronde W. Outpatient clinic for users of anabolic androgenic steroids. Neth J Med. 2019;77(7):247-253. NJM Online